UNSPSC 51283301: Cycloserine

This classification denotes an antitubercular agent with the molecular formula C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95IK5KI84Z, chemically known as 3-isoxazolidinone, 4-amino-, (s)- but generally known as cycloserine, which bears US NIH Compound Identifier 401. European Medicines Agency schedules Cycloserine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06863MIG.

UNSPSC 51283301 Cycloserine (Commodity) covers pharmaceutical products procured by state and local health departments and county public health authorities, though recent solicitations tagged under this code show limited direct activity for cycloserine itself. The Illinois Department of Public Health and Seminole County, Florida have posted pharmaceutical procurement opportunities in the recent period, but neither specifically solicited cycloserine; the Illinois contract, awarded to Chartwell Rx LLC in August 2026, covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride through a piggyback arrangement with the MMCAP Infuse consortium, while Seminole County's June 2026 IFB targeted Naloxone and drug deactivation systems for community health initiatives. Both procurements reflect state and local reliance on cooperative purchasing vehicles and competitive bidding for pharmaceutical supply, with quarterly or regular delivery schedules and fixed-price contracting models.

Solicitation activity under this code appears concentrated in Florida and Illinois in the recent period. The Seminole County procurement (IFB 60459723LAS, due July 26, 2023 with quarterly deliveries to Sanford) represents typical county-level community health purchasing, while the Illinois Department of Public Health award to Chartwell Rx LLC ($2,999,999.11 total over 12 months plus two renewal options) demonstrates state department scale and use of statewide consortiums for pharmaceutical supply. The code shows sparse direct solicitation activity; if cycloserine-specific opportunities are being posted by state or local health authorities, they are not prominently represented in recent open procurements, suggesting either stable supply relationships with existing vendors or procurement through standing cooperative agreements rather than competitive RFP or IFB cycles.